![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Synairgen Plc | LSE:SNG | London | Ordinary Share | GB00B0381Z20 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.235 | -4.94% | 4.52 | 4.35 | 4.69 | 4.75 | 4.36 | 4.75 | 212,429 | 16:35:15 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -17.65M | -0.0876 | -0.50 | 9.58M |
Date | Subject | Author | Discuss |
---|---|---|---|
30/4/2020 12:42 | This and STX flying at last. Hallelujah ! | ![]() peachie 74 | |
30/4/2020 12:42 | Sensational news, must be showing very positive effects for a new home trial! Should be at least £1 when you think this is a treatment rather than just a test... | ![]() 74tom | |
30/4/2020 12:41 | An actual RNS is massive!!!!!!!! | slinkyj | |
30/4/2020 12:40 | 70p offered now | ![]() bmnsa | |
30/4/2020 12:39 | So we have to wait for what looks like will be good news rather than worry at the prospect it may not be.would say more tilted in favour of a good readout now from the trial. So materially derisked I would say. | ![]() fidra | |
30/4/2020 12:37 | NHS obviously likes sng001 two rampy research notes in two days | ![]() bobaxe1 | |
30/4/2020 12:36 | Amazing rise. Overall good news but a June readout is I guess the only fly in the ointment. I was expecting it earlier. | ![]() nobbygnome | |
30/4/2020 12:36 | Tidy £800 profit today. I'm off to cut the grass. Gla | northern66 | |
30/4/2020 12:36 | The ten percenters will take their profit but this is major news. | ![]() rafboy | |
30/4/2020 12:31 | Needs to break 72p | ![]() d1nga | |
30/4/2020 12:29 | Has this push got legs at last??? | ![]() mostro | |
30/4/2020 12:29 | Like I said earlier about potential holders waiting for strong moves north.Think we will see a snowball effect now.Also trades are increasing in size. | ![]() cambradjones | |
30/4/2020 12:29 | Bought for 53p earlier | ![]() bmnsa | |
30/4/2020 12:28 | I'm bid 63.55 | ![]() bmnsa | |
30/4/2020 12:26 | 135k just bought 🙂 | ![]() makendon | |
30/4/2020 12:21 | I would say that’s pretty positive.you don’t extend if it is not working,and they now think taking it earlier could work in the home,which would result in less hospitalisation numbers. Win win | ![]() fidra | |
30/4/2020 12:20 | Perhaps now we will head for the 1 pound? | slinkyj | |
30/4/2020 12:19 | Good that the results from both arms, hospital and home, will be announced seperately. There was a concern that the hospital ones would be held over until home had completed. So still on track for June result and maybe July for home treatment?? Excellent news. | ![]() pdt | |
30/4/2020 12:17 | Market going to wake up soon. Ticking all boxes | ![]() bobaxe1 | |
30/4/2020 12:16 | That is really great news. | ![]() rolaw1 | |
30/4/2020 12:15 | Anna McDonald 'The fund manager also discusses in the podcast how she has invested in Synairgen (SNG:AIM) and other stocks looking to treat coronavirus or help pharma companies to find a vaccine.' | slinkyj | |
30/4/2020 12:15 | These dips are catching people out now. Getting locked out. | ![]() peachie 74 | |
30/4/2020 12:14 | 75% recruited good progress on schedule for completing the hospital trial, exciting addition with home trial and results June as expected! All positive. | ![]() crookie3634 | |
30/4/2020 12:13 | Approval received to extend SG016 clinical study of SNG001 in COVID-19 to initiate patients in the home environment Southampton, UK - 30 April 2020: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, announces that it has received approvals to extend the SG016 trial to patients with SARS-CoV-2 in the home environment. The objective is to initiate dosing with SNG001 (or placebo) earlier in the infection cycle, and before severe lower respiratory tract symptoms have developed. In due course, details of the design, implementation and timing of this novel study will be disclosed more fully. The treatment of patients in the hospital setting in the SG016 study is progressing well, with more than 75 patients out of the target 100 now dosed with Synairgen's wholly-owned drug SNG001 or placebo. Results from this part of the study are still expected in June 2020 | ![]() euclid5 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions